Opening doors to collaboration

Association of American Cancer Institutes
Working together to find a cure

2012
# 2012 AACI REPORT

## Table of Contents

1. Message from AACI
2. AACI/CCAF Annual Meeting
3. Clinical Research Initiative
4. AACI Fellowship
5. Corporate Roundtable
6. Informing Public Policy
7. Capitol Hill Day
8. Raising Awareness
9. AACI Web Portal Project
10. New President and AACI Growth
11. New and Sustaining Members
12. New AACI Leadership
13. 2012 Committees
14. AACI Membership

## Mission

*The Association of American Cancer Institutes is dedicated to promoting the common interests of the nation’s leading academic and free-standing cancer centers.*

## 2012 Officers

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>William S. Dalton, PhD, MD</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Term ended October 31</td>
</tr>
<tr>
<td>Immediate Past-President</td>
<td>Michael A. Caligiuri, MD</td>
<td>The Ohio State University Comprehensive Cancer Center – James Cancer Hospital &amp; Solove Research Institute</td>
</tr>
<tr>
<td>Vice-President/President-Elect</td>
<td>Michelle M. Le Beau, PhD</td>
<td>University of Chicago Comprehensive Cancer Center</td>
</tr>
</tbody>
</table>

## 2012 Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>David S. Alberts, MD</td>
<td>Arizona Cancer Center</td>
</tr>
<tr>
<td>Nancy E. Davidson, MD</td>
<td>University of Pittsburgh Cancer Institute</td>
</tr>
<tr>
<td>Robert B. Diasio, MD</td>
<td>Mayo Clinic Cancer Center</td>
</tr>
<tr>
<td>Beverly Mitchell, MD</td>
<td>Stanford Cancer Institute</td>
</tr>
<tr>
<td>William G. Nelson, MD, PhD</td>
<td>Sidney Kimmel Comprehensive Cancer Center at John Hopkins</td>
</tr>
<tr>
<td>Frank M. Torti, MD</td>
<td>Comprehensive Cancer Center of Wake Forest University</td>
</tr>
<tr>
<td>Louis M. Weiner, MD</td>
<td>Georgetown Lombardi Comprehensive Cancer Center</td>
</tr>
<tr>
<td>George Wilding, MD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
</tbody>
</table>

## New Board Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin J. Cullen, MD</td>
<td>University of Maryland Greenebaum Cancer Center</td>
</tr>
<tr>
<td>Michael B. Kastan, MD, PhD</td>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td>Edison T. Liu, MD</td>
<td>The Jackson Laboratory Cancer Center</td>
</tr>
<tr>
<td>Edward Partridge, MD</td>
<td>UAB Comprehensive Cancer Center</td>
</tr>
</tbody>
</table>

Photo credits: Cover - © Images.com/Corbis; Page 2 - Mike Gatty, David Joel (lower right); Page 3 - Mike Gatty (upper right); National Cancer Institute (lower right); Page 4 – Mike Gatty; Pages 6-7 - Diane Black; Page 10 - Senate Photography Studio (top), Lisa Nipp; Page 12 – Lisa Nipp; Page 15 - University of Chicago Medicine Comprehensive Cancer Center; Page 16 – The Jackson Laboratory.

Report design: Tara Taylor, Tru Blu Studio
THE ASSOCIATION OF AMERICAN CANCER INSTITUTES IS OPENING DOORS EVERY DAY TO NEW OPPORTUNITIES FOR COLLABORATION ACROSS THE ENTIRE CANCER RESEARCH COMMUNITY, WITH THE EXPRESS GOAL OF FINDING CURES AND, WHERE THAT IS NOT POSSIBLE, TO CONVERTING THE DISEASE INTO A MANAGEABLE CHRONIC CONDITION.

AACI works to advance the common interests of the nation’s cancer centers in three strategic ways:
- Promoting the widespread recognition of the cancer center network as the primary advocate for cancer patients and the public
- Facilitating interaction among the centers
- Fostering partnerships between cancer centers and other cancer organizations

In 2012, AACI focused on enhancing partnerships among its members using the association’s website as a forum. The very name of the effort—the AACI Web Portal Project—conjures images of a gateway opening to new horizons. As highlighted later in this report, the new website portal features a discussion forum, calendar of events and a document library. The library contains an array of background material such as meeting presentations and standard operating procedures to guide clinical trials operations at AACI member centers.

AACI’s Clinical Research Initiative (CRI) provides another major path to collaboration. Now in its fourth year, CRI has become one of AACI’s signature initiatives, helping address a range of challenges to conducting clinical trials at cancer centers. These include the growing complexity of trials, various administrative barriers, increasing regulatory and compliance requirements and lagging patient accrual.

AACI is unique among professional cancer organizations in its coordinated engagement with academic cancer centers through programs and initiatives developed by cancer center leadership to address shared challenges. Against that backdrop, AACI’s New Initiative Committee considers projects that will be of broad interest and add value to the AACI membership.

Expanded service to AACI members was also reflected in the awarding last year of four AACI Translational Cancer Research Fellowships—funded by Amgen, Astellas, Lilly USA, and Novartis—and the launch of a new membership category—the AACI Corporate Roundtable. With six inaugural industry representatives—Amgen, Astellas, Bristol-Myers Squibb, Celgene, Gilead, and Lilly USA—the Corporate Roundtable identifies ways that AACI and industry can leverage mutual strengths to continually improve the drug discovery process and access to the best cancer care possible.

AACI continued in 2012 to champion cancer research in the halls of Congress, with representatives from dozens of AACI centers visiting Capitol Hill in May to meet with legislators.

In addition, AACI’s annual meeting again attracted more than 250 cancer center leaders and research professionals to a two-and-a-half day conference that this year featured panel discussions on a number of topics including cancer screening, companion diagnostics, and the integration of prevention and control with basic clinical research.

AACI extends its sincere thanks to all of its members, particularly those serving on the association’s board and committees. We also extend an enthusiastic welcome to AACI’s new president, Michelle Le Beau, PhD, director of the University of Chicago Comprehensive Cancer Center, who assumed leadership of the association in November. We look forward to working with Michelle to enhance AACI’s supporting role in its members’ continuing progress toward a future without cancer.

William S. Dalton, PhD, MD
President, AACI
President, CEO, and Center Director
Moffitt Cancer Center

Barbara Duffy Stewart, MPH
Executive Director, AACI
The 2012 AACI/CCAF Annual Meeting convened October 14-16, in Chicago. The event was jointly sponsored by Vanderbilt University School of Medicine and AACI and was attended by more than 250 cancer center leaders and research professionals. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the meeting program.

In welcoming meeting attendees, AACI President Dr. William S. Dalton provided a progress report on AACI’s Web Portal Project, including an overview of the new member portal, which was launched during the meeting. The member portal includes a discussion forum, calendar of events, a document library and a cancer center locator.

AACI/CCAF Annual Meeting speakers and attendees: Above, Dr. Mark B. McClellan; below (L-R), Dr. Arnold B. Rabson; Dr. Michael Henry, Dr. George Weiner, Dr. Chad Ellis and David McFadden; Dr. Otis W. Brawley.
In a keynote presentation entitled, “Healthcare Reform and Innovation in Oncology”, Dr. Mark B. McClellan, Director of the Engelberg Center for Health Care Reform at the Brookings Institution, addressed health care costs, personalized cancer care and clinical trials, among other challenges facing cancer centers.

AACI Executive Director Barbara Duffy Stewart, MPH, announced that the association has launched a new corporate roundtable membership to help promote the success of the nation’s cancer center network through innovative and collaborative solutions to shared challenges. The inaugural AACI Corporate Roundtable members are Amgen, Astellas, Bristol-Myers Squibb, Celgene, Gilead Sciences and Lilly USA. Representatives from these organizations had an opportunity to meet with AACI leadership during the meeting. The annual meeting program committee, chaired by Dr. Dan Theodorescu, Director of the University of Colorado Cancer Center, assembled an outstanding array of speakers and compelling topics.

A panel discussion concerning conflicting recommendations for screenings featured presentations by Dr. Timothy Wilt, of the U.S. Preventive Services Task Force;

Dr. William Catalona, from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and Dr. Otis W. Brawley, representing the American Cancer Society. Dr. Shelton Earp, AACI past president and director of the UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, moderated the discussion.

Another panel discussion covering companion diagnostics, moderated by Lauren Hackett of the Vanderbilt-Ingram Cancer Center, included presentations by Dr. Mia Levy, also of Vanderbilt; Dr. Ian McCaffery, from Genentech; and Bristol-Myers Squibb’s Dr. Steven D. Averbuch.

Other talks focused on experiences at selected cancer centers with integrating prevention and control with basic and clinical research; the intersection of obesity, energetics and cancer; and the economics of addressing disparities at cancer centers.

Annual Meeting Awards

AACI’s 2012 Distinguished Scientist Award was presented to Margaret R. Spitz, MD, MPH. Dr. Spitz was professor and founding chair of the Department of Epidemiology during a 27-year career at The University of Texas M. D. Anderson Cancer Center. She joined the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine in 2009 to provide strategic direction for its population sciences program. Following the award presentation, Dr. Spitz delivered a special keynote talk on integrative epidemiology.

Also this year, AACI presented a Special Recognition Award to Alan S. Rabson, MD, deputy director of the National Cancer Institute. His award marks his more than five decades as a pathologist, cancer researcher, administrator and clinical advisor, as well as his numerous discoveries in virology and authorship of more than 100 scientific journal articles. Dr. Rabson’s son, Dr. Arnold B. Rabson, accepted the award on his father’s behalf.
Initiative and Program Supporters

AACI’s programs and initiatives are able to grow each year as a result of our supporters’ investment in our strategic mission. Programming benefits our member institutions, their investigators, and the patients they treat every day.

The AACI/CCAF annual meeting provides a venue for AACI to recognize this critical support and to demonstrate its value to the cancer center community as a whole. In 2012, Amgen, Astellas, Pfizer, and Varian Medical Systems Foundation provided unrestricted educational grants.

Exhibitors at this year’s meeting included Aegis Compliance & Ethics Center, LLP, Idea Elan, iLab Solutions, LLC, and Virtify.

In addition, program and activity support was received from Amgen, Astellas, Bristol-Myers Squibb, Celgene, Elekta, Forte Research Systems, Gilead, Velos, and Virtify. AACI is grateful to these companies for supporting its work on behalf of the nation’s leading academic and free-standing cancer centers.

Below, clockwise from upper left (L-R): Tom Witmer and Joyce Tull; Dr. Ralph deVere White, John McIlwain and Bob Wynne; Dr. Tony Reid, Ryan Meade and Michael Roach; Tad Fallows.
In February 2012, the CRI Steering Committee issued a call for abstracts to AACI members for presentation at the fourth annual CRI general membership meeting, held in Chicago.

The request focused on clinical trials operational problems and solutions, researched and implemented in a systematic fashion. The CRI Steering Committee received 18 abstracts and selected three for presentation at the meeting. All authors were invited to submit posters of their abstracts for display at the meeting.

This year’s abstracts were developed by the centers utilizing the Toyota manufacturing problem-solving approach and A3 template which provides a guideline for systematically addressing the root causes of problems in clinical trials offices. The “plan, do, act” problem-solving approach outlined in the abstracts allows teams to focus on solving the right problems, while making progress (or lack thereof) visible to the organization. The abstract and poster sessions were among the highlights of this year’s annual meeting and provided opportunities for centers to further discuss concepts that are being explored and implemented at the cancer centers.

2012 CRI Abstract Winners:

First Place
Managing Risk: A Path Toward Enhanced Communication, Risk Reduction, and Process Improvement Between Investigators and Monitors
Nareg Grigorian; Sharon Kobelin, MPH; Alyssa K Gateman, MPH, CCRP
Dana-Farber/Harvard Cancer Center

Second Place
How Can Appreciative Inquiry be Used to Improve Cancer Clinical Trials Efficiency?
Wendy Sarratt, DrPH and E. Claire Dees, MD
UNC Lineberger Comprehensive Cancer Center

Third Place
Quality Assurance Reviews: Process Improvements
Monica A. Orians, BS, MT(ASCP), CCRC; Annette Betley, BS ; CRA; Kathy Blanchard, BA, MBA; Doug Blayney, MD; Lisa Cummins, RN; J. Derrick Hibbler BS; Beesha Hsieh, BBA, MS; Mathew H Innes, BSE, MBA; MBA; Jeanie Kain BA, CIR CCRP; Rivka Sidlen, MS, PharmD; Janet Tarolli, RN, BSN, CCRC; Patty Bebee, RN, BA, CCRP; Tina Foley, BBA, CCRC; Mark Zalupski, MD
University of Michigan Comprehensive Cancer Center Quality Assurance Review Committee
Now in its fourth year, AACI’s Clinical Research Initiative (CRI) continues to broaden its scope of service to the cancer clinical research community. For example, CRI increased participation in its listserv in 2012 to 350 subscribers representing 79 AACI cancer centers. It also introduced a redesigned and more comprehensive quarterly newsletter and expanded an online resource library.

AACI CRI was created to provide a focused forum for sharing information and examining best practices that promote the efficient operation of cancer center clinical research facilities. CRI was also formed to leverage the influence of the AACI cancer center network to advocate for improvement in the national clinical trials enterprise. Key to the initiative’s success is the development of new tools and methods for sharing information across the AACI network and the dissemination of best practices that lead to increased access to new cancer therapies.

The fourth annual AACI CRI meeting convened in July in Chicago and its popularity continued to grow with 146 attendees, more than double the attendance at the inaugural meeting in 2009.

During the meeting, the National Cancer Institute’s (NCI) Margaret Mooney, MD, Branch Chief of Clinical Investigations, and Linda K. Weiss, PhD, Chief, Office of Cancer Centers, discussed plans to transform the clinical trials enterprise, particularly as they pertain to Cancer Center Support Grant guidelines and the NCI Clinical Trials Cooperative Group Program.

The NCI update was followed by a presentation on clinical trials disclosure and clinicaltrials.gov — a registry and results database of federally and privately supported clinical trials — by Barbara Godlew, RN, President and Founder of The FAIRE Company, LLC.

Much of CRI’s activity is organized around seven Special Interest Groups (SIGs): Business and Administration Integration; Managing Networks and Subsites; Regulatory and Pre-activation Processes; Trial Metrics; NCI Clinical Trials Reporting Program; Training, Quality Assurance, and Monitoring; and Academic, Industry and Government Relationships.

Over the past year, several CRI SIGs crafted and distributed surveys which assisted SIG leaders in prioritizing topics for discussion and development of needed tools. Several members of the Regulatory and Pre-activation SIG reviewed the results of surveys and concluded that investigator-initiated trials required more protocol review reiterations than industry sponsored trials. Cancer centers are looking at ways to reduce trial activation times, and one initiative underway is to review cancer center practices for opening trials and share those that produce faster trial activation timelines.
The Quality Assurance and the Network and Subsites SIGs are teaming up to develop a tool to help cancer centers identify monitoring risks for trials and develop plans to address the risks. The Trial Metrics SIG is working to determine how best to assign workloads to clinical trials office staff. Fifteen cancer centers who work with one of two methods for assigning work will be completing a project to assess which method is more useful to the trials office.

**Steering Committee**

The CRI Steering Committee guides and implements CRI activities, leading to the dissemination of proven means of effectiveness and best practice models across AACI cancer center clinical trials offices. Tony Reid, MD, PhD, of the University of California, San Diego, Moores Cancer Center, chairs the committee. The CRI membership elected the following new members to the committee in October 2012 to serve three-year terms: Randall F. Holcombe, MD, Mt. Sinai Medical Center, Tisch Cancer Institute; Teresa Stewart, MS, CRCP, University of New Mexico Cancer Center; Leigh Burgess, MHA, MEd, MA, Duke Cancer Institute; Carrie Ma, BSPharm, MBA, The University of Arizona Cancer Center; and, Vicki Keedy, MD, MSCI, Vanderbilt-Ingram Cancer Center.

AACI appreciates the leadership of outgoing steering committee members Drs. Jordan Berlin, David Dilts, Sarah McNees and James Thomas for their time and commitment to developing and implementing CRI over the past four years.
In 2012, AACI awarded four AACI Translational Cancer Research Fellowships to scientists at UCLA, University of Chicago, University of Michigan and Stanford University.

Funded by Amgen, Astellas, Lilly USA, and Novartis, these one-year, $50,000 grants are reserved exclusively for investigators at AACI cancer centers.

The intent of the fellowship is to provide additional support to individuals who are engaged in any area of clinical and/or translational cancer research in order to further the development of their careers and enhance their future success in an academic discipline.

This award is designed to help insure that qualified applicants receive research training and experience under the guidance of highly trained, well-respected investigators who have demonstrated success in their field of research. The goal is to assist the trainee in becoming a high-caliber, productive, independent researcher with an enduring focus on the importance of translational research relevant to cancer.

The 2011 inaugural fellowship winner, Dr. Yu Ding, of the Fred Hutchinson Cancer Research Center, delivered a talk at the 2012 AACI/CCAF annual meeting on his research involving glioma neural stem cell self-renewal networks.

### 2012 AACI Fellows

**Hubing Shi, PhD**
Postdoctoral Fellow  
Division of Dermatology  
David Geffen School of Medicine at UCLA  

**Project Title:** A PDGFRβ-EGFR hetero-complex in B-RAF mutant melanomas with acquired resistance to B-RAF inhibition.

**Scott V. Bratman, MD, PhD**  
Resident and Postdoctoral Fellow  
Department of Radiation Oncology  
Stanford Cancer Institute  

**Project Title:** A genomic strategy for residual disease monitoring in non-small cell lung cancer.

**Shaun Rosebeck, PhD**  
Research Fellow  
Pediatric Hematology/Oncology  
University of Michigan Health System  

**Project Title:** Deregulated RIP1 protein modifications in B-lymphomagenesis.

**David VanderWeele, MD**  
Fellow  
Department of Medicine  
Section of Hematology/Oncology  
The University of Chicago  

**Project Title:** Prostate cancer oncogenesis: one disease or two?
ACI instituted a new membership category in 2012 — the AICI Corporate Roundtable — to provide a forum for AICI cancer centers to address topics of mutual interest with their industry colleagues. The resulting interaction has the potential to advance the progress of research and speed the discovery of promising new therapies.

Specifically, the AICI Corporate Roundtable is designed to:

- Facilitate open discussion around important issues between industry representatives and the principal leaders of the nation’s foremost cancer research centers
- Bring together decision makers from across industry sectors for face-to-face interaction
- Afford industry the opportunity to become familiar with cancer center priorities and goals
- Provide cancer centers with the means to become familiar with industry priorities and goals
- Identify ways AICI and industry can leverage mutual strengths to continually improve access to the best cancer care possible
- Encourage development and expansion of AICI programs and resources

AICI is grateful for the support and commitment of Amgen, Astellas, Bristol-Myers Squibb, Celgene, Gilead, and Lilly for their participation as inaugural corporate roundtable members. Roundtable members gathered with AICI leadership for their first meeting on Sunday, October 14, 2012 at The Chicago Westin River North. Gathering prior to the opening session of the AICI/CCAF annual meeting allowed members to explore areas for potential collaboration with ongoing networking opportunities throughout the course of the annual meeting.
“Fiscal cliff” and “sequestration”: Two shorthand terms that dominated federal budget discussions in 2012 and served as red flags for potentially devastating cuts in cancer research funding.

Under the guidance of the AACI Government Relations Forum Steering Committee, the association kept members informed about funding developments on Capitol Hill and fought to protect federal support to cancer centers.

As part of AACI’s broad portfolio of public policy activity in 2012, the association joined the American Association for Cancer Research, the American Society of Clinical Oncology, and other cancer research advocates in submitting recommendations to the Centers for Medicare and Medicaid Services regarding coverage of clinical trials. Specifically, the organizations focused on: prevention of delays and administrative barriers; prevention, detection, and treatment of complications; geographic safeguard to preserve local access; clear coverage information for enrollees; referral to specialists; and consumer reporting.

AACI also sent a letter to House and Senate appropriations chairs, requesting at least $32 billion in funding for National Institutes of Health (NIH) in the FY 2013 Labor-HHS-Education Appropriations bill. Additionally, 16 cancer center government relations leaders convened for a full day at St. Jude Children’s Research Hospital in Memphis to discuss policy issues such as drug shortages and the implementation of health care reform.
MORAN, WASSERMAN SCHULTZ RECOGNIZED FOR CANCER RESEARCH SUPPORT

AACI presented 2012 AACI Distinguished Public Service Awards to U.S. Senator Jerry Moran (R-KS) and U.S. Representative Debbie Wasserman Schultz (D-FL) during the 2012 AACI/CCAF Annual Meeting, in Chicago.

Sen. Moran was recognized for his exceptional leadership in promoting cancer research both as a seven-term congressman and in his service on the Senate Appropriations Committee, as a member of the Subcommittee on Labor, Health and Human Services. His support of the work of the National Cancer Institute (NCI) and AACI’s member institutions was reflected in his lead sponsorship of a Senate resolution highlighting the nation’s commitment to cancer research and commemorating the 40th anniversary of the signing of the National Cancer Act. In 2012, Sen. Moran dedicated his support to the University of Kansas Cancer Center’s successful bid for NCI designation.

In March 2009, after announcing her own battle with breast cancer, Rep. Wasserman Schultz introduced the Education and Awareness Requires Learning Young Act, or EARLY Act (H.R. 1740). The legislation directs the Centers for Disease Control and Prevention to develop and implement a national education campaign about the threat breast cancer poses to all young women, and the particular heightened risks of certain ethnic, cultural and racial groups. This bill became law as part of the Patient Protection and Affordable Care Act in March 2010.

RESEARCH CHAMPION

U.S. Senator Arlen J. Specter
February 12, 1930 – October 14, 2012

AACI is honored to celebrate the life and work of Senator Arlen Specter (D-PA). Despite his own battles with cancer, Sen. Specter fought tirelessly through much of his 30-year Senate career on behalf of biomedical research and the special needs of cancer patients and their families.

As AACI Executive Director Barbara Duffy Stewart, MPH, wrote in a letter to the Pittsburgh Post-Gazette supporting the senator’s 2010 reelection bid: “Making progress against cancer is a complex process, and the results are not always immediately tangible. Research takes time to go from the laboratory to the patient…. Sen. Specter understands this and there is no one in the Senate who is better equipped to help effect that ‘bench to bedside’ transition than Sen. Specter.”

Sen. Specter received two AACI Distinguished Public Service Awards, in 2003 and 2009. The honors recognized his exceptional commitment to the U.S. biomedical research infrastructure, including his efforts to double the NIH budget and for the provision that he introduced to add $6.5 billion in economic stimulus funding for the National Institutes of Health in 2009.

Sen. Specter (second from right) receives the 2003 AACI Distinguished Public Service award from past AACI presidents (L-R) Drs. Harold L. Moses, Ronald B. Herberman and John E. Niederhuber.
Eighty-five cancer researchers, oncology nurses, clinicians, advocates and cancer survivors completed 150 meetings with legislators and their staff members during this year’s visit to Capitol Hill on May 17. AACI, the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), Friends of Cancer Research (Friends), and the Oncology Nursing Society (ONS) hosted the event.

At a reception on May 16, the organizations honored U.S. Reps. Diana DeGette (D-CO) and Brian Bilbray (R-CA) for their passion and commitment to strengthening the nation’s efforts to eradicate cancer and improve public health.

In remarks delivered at a breakfast prior to the Hill visits, Laura Friedel, Republican Clerk for the Senate Appropriations Subcommittee on Labor, HHS, Education and Related Agencies, reviewed the latest budget options being considered by Congress. She also underlined how much legislators rely on feedback from constituents like cancer center directors.

“If we don’t hear from you, then we assume everything is all right,” she said.

Responding to Friedel, AACI president Bill Dalton noted that both NIH Director Dr. Francis Collins and NCI Director Dr. Harold Varmus have recently identified “sequestration”, or automatic federal spending cuts, as 2012’s top threat to biomedical and cancer research funding. With the prospect of sequestration slashing the federal investment in biomedical research by a devastating 7.8 percent, the issue was one of the main discussion points in interactions with legislators on Hill Day as AACI members detailed the profound impact these cuts would have on cancer centers.
Raising Awareness

AACI’s evolving communications agenda focuses on promoting the work of its member centers to both general audiences and the cancer research community, with outreach efforts often dovetailing with the association’s ongoing public issues activities.

In February, AACI delivered a presentation as part of a webinar hosted by the National Cancer Institute (NCI) Public Affairs Network entitled, “Media Relations: How to work with the NCI and other professional cancer organizations.” Approximately 50 cancer center communications professionals tuned in to learn about communications activities at AACI, NCI, the American Association for Cancer Research and the American Society of Clinical Oncology.

As in recent years, the AACI/CCAF Annual Meeting received coverage in Oncology Times, with smaller regional publications like the Hays (Kansas) Post and Houston Business Journal also covering AACI news. In addition, NCI’s Benchmarks, an online publication providing health and science writers with background information on emerging topics in cancer research, ran a story about Dr. Alan S. Rabson receiving AACI’s Special Recognition Award.

AACI cast a wider news dissemination net in 2012 by engaging Newswise, a press release distribution service that also tracks media response to clients’ outreach. According to Newswise, AACI’s press release about its 2012 Public Service Awards received more views than 96 percent of the same story type posted on the company’s website (see table below).

As noted earlier in this report, AACI’s Web Portal Project aims to raise the profile of the association’s website as an important tool for communication and improving awareness of the cancer centers. In addition, AACI Update, our monthly online newsletter, continues to grow in popularity with an email circulation of more than 1,100, up from about 330 when it was launched in 2004.

Increasing Media Visibility

<table>
<thead>
<tr>
<th>PRESS RELEASE TITLE</th>
<th>NUMBER OF VIEWS</th>
<th>PERCENTILE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cullen, Kastan and Liu Join AACI Board of Directors</td>
<td>716</td>
<td>16th*</td>
</tr>
<tr>
<td>AACI to Honor Sen. Jerry Moran and Rep. Debbie Wasserman Schultz</td>
<td>1467</td>
<td>96th</td>
</tr>
<tr>
<td>AACI Marks the Passing of Senator Arlen Specter, Champion of Biomedical Research</td>
<td>834</td>
<td>31st</td>
</tr>
<tr>
<td>Le Beau Succeeds Dalton as AACI President</td>
<td>992</td>
<td>57th</td>
</tr>
<tr>
<td>AACI to Honor Drs. Alan Rabson and Margaret Spitz</td>
<td>837</td>
<td>25th</td>
</tr>
<tr>
<td>AACI Awards Four Translational Cancer Research Fellowships</td>
<td>961</td>
<td>23rd</td>
</tr>
</tbody>
</table>

* Example: a story listed in the 65th percentile received more views than 65 percent of stories in the same Newswise library and of the same story type.

Source: Newswise Monthly Report, Association of American Cancer Institutes, October 2012 (based on preliminary data gathered through November 15, 2012)
In 2012 AACI President William S. Dalton, PhD, MD, focused the association’s attention on enhancing partnerships among its members, using the AACI website as a forum.

AACI’s Web Portal Project fulfills the organization’s strategic goal of facilitating interaction among cancer centers and answers the call of many AACI members for an online infrastructure promoting collaboration among institutions and stakeholders and the sharing of information.

It also responds to the cancer community’s ongoing efforts to identify information exchange solutions that are national in scale and robust enough to meet the needs of critical constituencies including researchers, administrators and clinicians.

AACI’s member portal is password protected and open exclusively to AACI members. It currently features a discussion forum, calendar of events and a document library containing an array of background material including meeting presentations, compensation data, and standard operating procedures for conducting clinical trials at AACI member centers.

Future development of the AACI web portal will include a searchable database of shared resources and program information at AACI centers, and a directory of cancer center personnel by job category.
**New President and AACI Growth**

**New AACI President**

Michelle M. Le Beau, PhD, director of the University of Chicago Comprehensive Cancer Center, became the new president of the Association of American Cancer Institutes in November. She was elected as AACI’s Vice President/President-Elect in October 2011.

Dr. Le Beau succeeded William S. Dalton, PhD, MD, longtime head of the Moffitt Cancer Center, in Tampa. Dr. Dalton stepped down in August as president, chief executive and center director at Moffitt to focus on leading Moffitt’s new Personalized Medicine Institute, as well as continuing to serve as chief executive officer of M2Gen, Moffitt’s biotechnology subsidiary.

“It’s an exciting challenge and honor to lead AACI, a vibrant organization whose multidisciplinary programs have had a lasting impact on cancer research and care,” Dr. Le Beau said. “I’m delighted to work with the leaders of our nation’s cancer research enterprise in advancing our collective mission of translating cancer research into improved patient care, cancer prevention, and community outreach.”

Dr. Le Beau has also served as director of the University of Chicago’s Cancer Cytogenetics Laboratory since 1985. Her noteworthy scientific accomplishments include identifying recurring genetic abnormalities in blood cancers, and groundbreaking research that led to the discovery that there are several distinct genetic subtypes of therapy-related myelodysplastic syndrome, a precursor to leukemia, and acute myeloid leukemia.

**AACI Growth and Change**

AACI’s genesis can be traced to 1958 when a small group of cancer center directors first met and organized itself as the Association of Cancer Institute Directors. With the passage of the National Cancer Act of 1971 the directors began to meet on an annual basis and changed their name around that time to the Association of American Cancer Institutes. By 1999, an administrative office with a full-time executive director and staff was established in Pittsburgh to increase communication with the National Cancer Institute, the U.S. Congress and the patient advocacy community.

Today, AACI welcomes its first woman president, Dr. Michelle Le Beau. That precedent caps a dozen years of significant growth and change for AACI as a full service membership organization dedicated to promoting the common interests of the nation’s leading academic and free-standing cancer centers.

<table>
<thead>
<tr>
<th><strong>Membership (Centers)</strong></th>
<th>THEN 77 in 2000</th>
<th>NOW 95 in 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Programs and Initiatives</strong></td>
<td>0 in 2000</td>
<td>10 in 2012</td>
</tr>
<tr>
<td><strong>Fellowship Grants</strong></td>
<td>0 in 2000</td>
<td>4 in 2012</td>
</tr>
<tr>
<td><strong>Annual Meeting Attendance</strong></td>
<td>86 in 2000</td>
<td>275 in 2012</td>
</tr>
<tr>
<td><strong>AACI Update Circulation</strong></td>
<td>330 in 2004</td>
<td>1,120 in 2012</td>
</tr>
</tbody>
</table>
The center’s objectives are to: 1) Determine the role of cell cycle and genome dynamics in the origins of cancer; 2) analyze the molecular pathways that influence cancer susceptibility and tumor progression; 3) develop and test improved methods for cancer detection; 4) model human genomic complexity as a means to identify genetic loci underlying cancer susceptibility and progression.

Sustaining Members
AACI added the CEO Roundtable on Cancer to its roster of sustaining members in 2012. The organization is comprised of chief executives from more than 30 major American companies representing diverse industries, from nonprofit organizations committed to fighting cancer, and from several National Cancer Institute-designated cancer centers.

The CEO Roundtable on Cancer joined four other like-minded organizations as AACI sustaining members: the American Association for Cancer Research; the American Society of Clinical Oncology; C-Change; and LIVESTRONG®. Sustaining members participate in AACI sponsored meetings, workshops, and forums and meet annually with AACI leadership.
NEW AACI LEADERSHIP

AACI welcomed four cancer center leaders to its board of directors in 2012.

Kevin J. Cullen, MD; Michael B. Kastan, MD, PhD; and Edison T. Liu, MD, were elected to three-year terms. In addition, Edward Partridge, MD, was appointed to fulfill the unexpired board term of Frank M. Torti, MD, MPH. Dr. Torti voluntarily stepped down after leaving the directorship of the Comprehensive Cancer Center of Wake Forest University to become dean of the University of Connecticut School of Medicine.

KEVIN J. CULEN, MD
DIRECTOR, UNIVERSITY OF MARYLAND MARLENE AND STEWART GREENEBAUM CANCER CENTER

Dr. Cullen specializes in head and neck cancer and is a professor of medicine at the University of Maryland School of Medicine and head of its program in oncology. Under his leadership, the Greenebaum Center received National Cancer Institute designation in 2008.

MICHAEL B. KASTAN, MD
EXECUTIVE DIRECTOR, DUKE CANCER INSTITUTE

Dr. Kastan previously served as director, Comprehensive Cancer Center, St. Jude Children’s Research Hospital. His laboratory research concentrates on DNA damage and repair, tumor suppressor genes, and causes of cancer related to genetic predisposition and environmental exposures.

EDISON T. LIU, MD
PRESIDENT AND CEO, THE JACKSON LABORATORY
DIRECTOR, THE JACKSON LABORATORY CANCER CENTER

Dr. Liu has been president of the international Human Genome Organization since 2007. He is the founding executive director of the Genome Institute of Singapore, building it in less than 10 years from a staff of three into a major research institute of 27 laboratory groups and a staff of 270.

EDWARD PARTIDGE, MD
DIRECTOR, UAB COMPREHENSIVE CANCER CENTER

Dr. Partridge is former director of the Division of Gynecologic Oncology and holds the Evalina B. Spencer Endowed Chair in Oncology at UAB. His clinical interests are cancer control and prevention, cervical cancer, community based participatory research, gynecologic oncology, and minority health disparities.
Committees

Annual Meeting
The Annual Meeting Program Committee develops the agenda for the yearly meeting of the association’s membership.

Chair: Dan Theodorescu, MD, PhD
University of Colorado Cancer Center

William S. Dalton, PhD, MD
Moffitt Cancer Center

Chi Van Dang, MD, PhD
Abramson Cancer Center of the University of Pennsylvania

Michael W. Darling, MHA
Indiana University Melvin and Bren Simon Cancer Center

Peter D. Emanuel, MD
Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences

Gordon D. Ginder, MD
Massey Cancer Center
Medical College of Virginia Campus

Dina Gould Halme, PhD
University of Virginia Cancer Center

Mark Kochevar, MBA
University of Colorado Cancer Center

Michelle M. Le Beau, PhD
University of Chicago Comprehensive Cancer Center

Dave Rubenson, MBA
Stanford Cancer Institute

Brian C. Springer, MHA
Roswell Park Cancer Institute

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Tim Strawderman, PhD
Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center at Dallas

Donald L. Trump, MD, FACP
Roswell Park Cancer Institute

Kristiina Vuori, MD, PhD
Sanford-Burnham Medical Research Institute

Clinical Research Initiative
The CRI Steering Committee guides and implements activities that encourage best practices and efficient use of resources and operations in cancer center clinical research facilities.

Chair: Tony R. Reid, MD, PhD
UCSD Moores Cancer Center
University of California at San Diego

Rhoda Arzooomanian, MSM, RN, BSN
University of Wisconsin
Paul P. Carbone Comprehensive Cancer Center

Leigh A. Burgess, MHA, MEd, MA
Duke Cancer Institute
Duke University Medical Center

Henry Durivage, PharmD
Yale Cancer Center
Yale University School of Medicine

Alyssa K. Gateman, MPH
Dana-Farber Cancer Institute
Harvard Medical School

Janie Hofacker, RN, MS
Association of American Cancer Institutes

Randall F. Holcombe, MD
Tisch Cancer Institute, Mount Sinai Medical Center

Vicki Keedy, MD, MSCl
Vanderbilt-Ingram Cancer Center

Carrie Ma, MBA, BSPharm
The University of Arizona Cancer Center

Joy Ostroff, RN, BSN, OCN
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Douglas C. Stahl, PhD, MBA
City of Hope Comprehensive Cancer Center

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Teresa L. Stewart, MS, CRCP
University of New Mexico Cancer Center

Jeanine H. Stiles
UC Davis Comprehensive Cancer Center

James P. Thomas, MD, PhD
Medical College of Wisconsin Cancer Center

Government Relations
The AACI Government Relations Forum Steering Committee monitors public policy actions that have an impact on cancer centers.

Chair: Lisa A. Damiani
Roswell Park Cancer Institute

Jennifer K. Carlson
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute

Ross A. Frommer, JD
Herbert Irving Comprehensive Cancer Center
Columbia University
Heidi L. Gartland, MHA  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Seidman Cancer Center  
University Hospitals Case Medical Center

Anne L. Levine  
Dana-Farber Cancer Institute  
Harvard Medical School

Mark Moreno  
University of Texas M.D. Anderson  
Cancer Center

Elizabeth B. O’Brien, JD  
The Wistar Institute

Kristen L. Pugh, MPA  
City of Hope Comprehensive Cancer Center

Gilda Ventresca-Ecroyd, MA  
NYU Cancer Institute

Paul A. Vick, MA  
Duke Cancer Institute  
Duke University Medical Center

Jamie Wilson, MS  
Moffitt Cancer Center

**Finance and Investment**
The Finance and Investment Committee oversees the development and implementation of all policies related to AACI’s finances and expenditures. It reviews investment performance and advises on AACI’s asset portfolio.

Chair: Dorothy E. Puhy  
Dana-Farber Cancer Institute  
Harvard Medical School

Robert J. DuWors, MPA  
Jonsson Comprehensive Cancer Center, UCLA

John A. Kolosky, MBA  
Moffitt Cancer Center

Randall C. Main  
Fred Hutchinson Cancer Research Center

Michael P. Vander Hoek, MHSA  
Lombardi Comprehensive Cancer Center  
Georgetown University

**Nominating**
The Nominating Committee meets each year and is charged with identifying individuals among the member institutions who are best qualified to serve on the AACI Board of Directors.

Chair: Kristiina Vuori, MD, PhD  
Sanford-Burnham Medical Research Institute

Michael A. Caligiuri, MD  
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute

Donald L. Trump, MD, FACP  
Roswell Park Cancer Institute

**New Initiative**
The New Initiative Committee identifies and develops new clinical/scientific/educational programs of broad interest to AACI membership.

Chair: George J. Weiner, MD  
Holden Comprehensive Cancer Center  
University of Iowa

H. Shelton Earp III, MD  
UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

Peter D. Emanuel, MD  
Winthrop P. Rockefeller Cancer Institute  
University of Arkansas for Medical Sciences

Gordon D. Ginder, MD  
Massey Cancer Center  
Medical College of Virginia Campus

Roy A. Jensen, MD  
University of Kansas Cancer Center

Michelle M. Le Beau, PhD  
University of Chicago Comprehensive Cancer Center

Howard Ozer, MD, PhD  
University of Illinois Cancer Center

Timothy L. Ratliff, PhD  
Purdue Center for Cancer Research

Kristiina Vuori, MD, PhD  
Sanford-Burnham Medical Research Institute

Cheryl L. Willman, MD  
University of New Mexico Cancer Center

**Web Portal Project**
The AACI Web Portal Project Advisory Committee guides development of the project and recommends documents and other content for inclusion on the website. (See page 14 for list of committee members.)
2012 AACI Membership

Alabama
UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Arizona
The University of Arizona Cancer Center
Tucson, Arizona

Arkansas
Winthrop P. Rockefeller Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

California
City of Hope Comprehensive Cancer Center
and Beckman Research Institute
Duarte, California

Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California

Loma Linda University Cancer Center
Loma Linda, California

Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Sanford-Burnham Medical Research Institute
La Jolla, California

Stanford Cancer Institute
Palo Alto, California

UC Davis Comprehensive Cancer Center
The University of California
Davis Medical Center
Sacramento, California

UCI Chao Family Comprehensive Cancer Center
University of California at Irvine
Orange, California

UCSD Moores Cancer Center, University of California at San Diego
La Jolla, California

UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

USC/Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, California

Colorado
University of Colorado Cancer Center
University of Colorado Health Sciences Center
Aurora, Colorado

Connecticut
The Carole & Ray Neag Comprehensive Cancer Center
University of Connecticut Health Center
Farmington, Connecticut

Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

District of Columbia
George Washington Cancer Institute
Washington, District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University
Washington, District of Columbia

Florida
Moffitt Cancer Center
Tampa, Florida

University of Florida Shands Cancer Center
Gainesville, Florida

University of Miami Sylvester Comprehensive Cancer Center
University of Miami School of Medicine
Miami, Florida

Georgia
Georgia Health Sciences University Cancer Center
Augusta, Georgia

Winship Cancer Institute of Emory University
Atlanta, Georgia

Hawaii
University of Hawaii Cancer Center,
University of Hawaii at Manoa
Honolulu, Hawaii

Illinois
Cardinal Bernardin Cancer Center
of Loyola University Chicago
Maywood, Illinois

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois

Simmons Cancer Institute
of Southern Illinois University
Springfield, Illinois

University of Chicago Comprehensive Cancer Center
Chicago, Illinois

University of Illinois Cancer Center
Chicago, Illinois

Indiana
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana

Purdue Center for Cancer Research
West Lafayette, Indiana

Iowa
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Kansas
University of Kansas Cancer Center
Kansas City, Kansas

Kentucky
James Graham Brown Cancer Center
University of Louisville Health Care
Louisville, Kentucky

Markey Cancer Center
University of Kentucky
Lexington, Kentucky

Louisiana
Feist-Weiller Cancer Center
LSU Health Sciences Center in Shreveport
Shreveport, Louisiana

Louisiana Cancer Research Consortium
of New Orleans

Stanley S. Scott Cancer Center
New Orleans, Louisiana

Tulane Cancer Center
New Orleans, Louisiana

Maine
The Jackson Laboratory Cancer Center
Bar Harbor, Maine

Maryland
Murtha Cancer Center at Walter Reed Bethesda
Bethesda, Maryland

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland

University of Maryland Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland

Massachusetts
Boston University Cancer Research Center
Boston, Massachusetts

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Tufts Medical Center Cancer Center
Boston, Massachusetts

Michigan
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan

The Van Andel Research Institute
Grand Rapids, Michigan

Minnesota
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota

Mayo Clinic Cancer Center
Rochester, Minnesota
<table>
<thead>
<tr>
<th>State</th>
<th>Cancer Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>Missouri</td>
<td>MissOuri Siteman Cancer Center of Barnes-Jewish Hospital at Washington University School of Medicine St. Louis, Missouri</td>
</tr>
<tr>
<td>Nebraska</td>
<td>UNMC Eppley Cancer Center University of Nebraska Medical Center Omaha, Nebraska</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire</td>
</tr>
<tr>
<td>New Jersey</td>
<td>The Cancer Institute of New Jersey Robert Wood Johnson Medical School New Brunswick, New Jersey</td>
</tr>
<tr>
<td>New Mexico</td>
<td>University of New Mexico Cancer Center Albuquerque, New Mexico</td>
</tr>
<tr>
<td>New York</td>
<td>Albert Einstein Cancer Center, Albert Einstein College of Medicine Yeshiva University Bronx, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Herbert Irving Comprehensive Cancer Center Columbia University New York, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Memorial Sloan-Kettering Cancer Center New York, New York</td>
</tr>
<tr>
<td>New York</td>
<td>NYU Cancer Institute New York, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Roswell Park Cancer Institute Buffalo, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Stony Brook University Cancer Center State University of New York Stony Brook, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Tisch Cancer Institute, Mount Sinai Medical Center New York, New York</td>
</tr>
<tr>
<td>New York</td>
<td>Wilmot Cancer Center University of Rochester Medical Center Rochester, New York</td>
</tr>
<tr>
<td>North Carolina</td>
<td>Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina</td>
</tr>
<tr>
<td>North Carolina</td>
<td>Duke Cancer Institute Duke University Medical Center Durham, North Carolina</td>
</tr>
<tr>
<td>North Carolina</td>
<td>UNC Lineberger Comprehensive Cancer Center School of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina</td>
</tr>
<tr>
<td>Ohio</td>
<td>Case Comprehensive Cancer Center, Case Western Reserve University, Seidman Cancer Center at University Hospitals Case Medical Center Cleveland, Ohio</td>
</tr>
<tr>
<td>Ohio</td>
<td>Cleveland Clinic Taussig Cancer Institute The Cleveland Clinic Foundation Cleveland, Ohio</td>
</tr>
<tr>
<td>Ohio</td>
<td>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital &amp; Solove Research Institute Columbus, Ohio</td>
</tr>
<tr>
<td>Ohio</td>
<td>UC Cancer Institute University of Cincinnati College of Medicine Cincinnati, Ohio</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>Peggy and Charles Stephenson Cancer Center University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma</td>
</tr>
<tr>
<td>Oregon</td>
<td>Knight Cancer Institute Oregon Health and Sciences University Portland, Oregon</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Fox Chase Cancer Center Temple Health Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Kimmel Cancer Center at Jefferson Thomas Jefferson University Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Penn State Hershey Cancer Institute Hershey, Pennsylvania</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>University of Pittsburgh Cancer Institute UPMC Cancer Centers Pittsburgh, Pennsylvania</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>The Wistar Institute Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>Puerto Rico Cancer Center University of Puerto Rico San Juan, Puerto Rico</td>
</tr>
<tr>
<td>South Carolina</td>
<td>Hollings Cancer Center Medical University of South Carolina Charleston, South Carolina</td>
</tr>
<tr>
<td>Tennessee</td>
<td>Comprehensive Cancer Center St. Jude Children's Research Hospital Memphis, Tennessee</td>
</tr>
<tr>
<td>Texas</td>
<td>Vanderbilt-Ingram Cancer Center Nashville, Tennessee</td>
</tr>
<tr>
<td>Texas</td>
<td>Cancer Therapy and Research Center at the University of Texas Health Science Center San Antonio, Texas</td>
</tr>
<tr>
<td>Texas</td>
<td>The Dan L. Duncan Cancer Center at Baylor College of Medicine Houston, Texas</td>
</tr>
<tr>
<td>Texas</td>
<td>Simmons Comprehensive Cancer Center The University of Texas Southwestern Medical Center at Dallas Dallas, Texas</td>
</tr>
<tr>
<td>Texas</td>
<td>University of Texas MD Anderson Cancer Center Houston, Texas</td>
</tr>
<tr>
<td>Texas</td>
<td>University of Texas Medical Branch Cancer Center Galveston, Texas</td>
</tr>
<tr>
<td>Utah</td>
<td>Huntsman Cancer Institute, University of Utah Salt Lake City, Utah</td>
</tr>
<tr>
<td>Vermont</td>
<td>Vermont Cancer Center, University of Vermont Burlington, Vermont</td>
</tr>
<tr>
<td>Virginia</td>
<td>Massey Cancer Center Virginia Commonwealth University Richmond, Virginia</td>
</tr>
<tr>
<td>Virginia</td>
<td>University of Virginia Cancer Center Charlottesville, Virginia</td>
</tr>
<tr>
<td>Washington</td>
<td>Fred Hutchinson Cancer Research Center Seattle, Washington</td>
</tr>
<tr>
<td>West Virginia</td>
<td>Mary Babb Randolph Cancer Center West Virginia University Morgantown, West Virginia</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin</td>
</tr>
</tbody>
</table>